A Solution for Rising Drug Costs

Employers may start to move away from fixed co-payments.

With the cost of prescription drugs rising at an alarming rate, employers are likely to ask employees to foot a greater percentage of pharmacy benefits bills.

But the tight labor market may make it hard for employers to get workers to accept coinsurance plans. The market could also make it difficult for companies to boost the percentage amounts employees already contribute to their drug bills.

Nevertheless, 65 percent of the employee benefits specialists polled in a recent survey by the International Society of Certified Employee Benefits Specialists (ISCEBS) said they think rising drug prices will push benefit-plan sponsors to shift from copayments to percentage-based coinsurance.

That shift will come in response to a powerful upward surge in the cost of pharmacy benefits to employers, according to the survey. Sixty- two percent of the 268 poll respondents said that prescription-drug-benefit costs would continue to rise at an annual rate of 15 percent to 20 per cent for the next few years.

Though not the biggest chunk of health-plan costs, prescription drug benefits are widely considered to be the fastest rising expense item. To curb those costs, employers are likely to move away from copayments, which are set dollar amounts which employees must pay when they buy prescription drugs, regardless of the price.

With drug prices inflating rapidly, a copayment of $5 or $10, for instance, may soon seem paltry, thus negating any incentive for an employee to think about the purchases he or she is making. And such second thoughts are a key to holding down costs, many employers think.

In contrast to a copayment, a coinsurance provision, which calls for employers to pay a percentage of the drug-benefits bill, generally takes a bigger bite from employees— perhaps as much as 20 percent—and enables employers to keep pace with pharmaceutical inflation.

Melody A. Carlsen, the author of the ISCEBS survey and associate director of research for the International Foundation of Employee Benefit Plans in Brookfield Wis., says there may be initial employee resistance to coinsurance.

But once the resistance is overcome, it may amount to less of an employee-communications hassle than frequent boosts in copayments, she thinks.

“Coinsurance will automatically keep pace with increases,” in the cost of drugs, she says. In the case of copayments, employers would “have to make a specific increase in the plan,” she adds. “This change would have to be communicated [to] employees…They would feel a direct impact.”

In the case of coinsurance, however, [employee] cost increases are “built into the design,” she notes. And as a result “increases are felt a little more gradually.”

At first, installing a drug coinsurance provision is likely to involve a “considerable amount of communication,” according to Carlsen. After that “it can pretty much run on its own,” she says.

One problem with installing across-the-board coinsurance provisions, however, is that they have “a disproportionate effect on lower paid people,” says Steve Gross, the head of employee compensation consulting for William M. Mercer Inc. in Philadelphia.


Your email address will not be published. Required fields are marked *